Immix Biopharma Inc (IMMX) USD0.0001

Sell:$1.51Buy:$1.65$0.07 (4.17%)

Prices delayed by at least 15 minutes
Sell:$1.51
Buy:$1.65
Change:$0.07 (4.17%)
Prices delayed by at least 15 minutes
Sell:$1.51
Buy:$1.65
Change:$0.07 (4.17%)
Prices delayed by at least 15 minutes

Company Information

About this company

Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and autoimmune disease. The Company's lead cell therapy asset is CAR-T NXC-201 for autoimmune disease, relapsed/refractory AL Amyloidosis, and relapsed/refractory multiple myeloma, which is being evaluated in its ongoing Phase Ib/IIa NEXICART-1 (NCT04720313) clinical trial. Its tissue specific therapeutic IMX-110 is in clinical trials as a monotherapy, and in combination with tislelizumab (BeiGene anti-PD-1 - IMMINENT-01 NCT05840835) for advanced solid tumors, such as relapsed/refractory colorectal cancer (CRC). IMX-110 in Phase Ib/IIa clinical trials, is a Tissue-Specific Therapeutic with TME Normalization, a technology that the Company is developing initially for mCRC and Soft Tissue Sarcoma (STS).

Key people

Ilya Rachman
Chairman of the Board, Chief Executive Officer
Vladimir Torchilin
Scientific Co-Founder
Gabriel Morris
Chief Financial Officer, Director
Nandan Oza
Head - Chemistry, Manufacturing, and Control
Graham Ross
Acting Chief Medical Officer, Head - Clinical Development
Helen C. Adams
Independent Director
Jane M. Buchan
Independent Director
Yekaterina Chudnovsky
Independent Director
Jason Hsu
Independent Director
Magda Marquet
Independent Director
Click to see more

Key facts

  • EPIC
    IMMX
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US45258H1068
  • Market cap
    $47.13m
  • Employees
    18
  • Shares in issue
    27.79m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.